Metabolism
Forkhead Box O6 (FoxO6) Depletion Attenuates Hepatic Gluconeogenesis and Protects against Fat-induced Glucose Disorder in Mice*

https://doi.org/10.1074/jbc.M115.650994Get rights and content
Under a Creative Commons license
open access

Excessive endogenous glucose production contributes to fasting hyperglycemia in diabetes. FoxO6 is a distinct member of the FoxO subfamily. To elucidate the role of FoxO6 in hepatic gluconeogenesis and assess its contribution to the pathogenesis of fasting hyperglycemia in diabetes, we generated FoxO6 knock-out (FoxO6-KO) mice followed by determining the effect of FoxO6 loss-of-function on hepatic gluconeogenesis under physiological and pathological conditions. FoxO6 depletion attenuated hepatic gluconeogenesis and lowered fasting glycemia in FoxO6-KO mice. FoxO6-deficient primary hepatocytes were associated with reduced capacities to produce glucose in response to glucagon. When fed a high fat diet, FoxO6-KO mice exhibited significantly enhanced glucose tolerance and reduced blood glucose levels accompanied by improved insulin sensitivity. These effects correlated with attenuated hepatic gluconeogenesis in FoxO6-KO mice. In contrast, wild-type littermates developed fat-induced glucose intolerance with a concomitant induction of fasting hyperinsulinemia and hyperglycemia. Furthermore, FoxO6-KO mice displayed significantly diminished macrophage infiltration into liver and adipose tissues, correlating with the reduction of macrophage expression of C-C chemokine receptor 2 (CCR2), a factor that is critical for regulating macrophage recruitment in peripheral tissues. Our data indicate that FoxO6 depletion protected against diet-induced glucose intolerance and insulin resistance by attenuating hepatic gluconeogenesis and curbing macrophage infiltration in liver and adipose tissues in mice.

Background:

Excessive endogenous glucose production is a major contributing factor for fasting hyperglycemia in diabetes.

Results:

FoxO6 deficiency attenuates hepatic gluconeogenesis and protects against fat-induced glucose disorder in mice.

Conclusion:

FoxO6 plays a significant role in regulating gluconeogenesis in the liver.

Significance:

FoxO6 is a potential therapeutic target for improving glucose metabolism in diabetes.

diabetes
gluconeogenesis
glucose metabolism
liver
obesity
FoxO6
mice

Cited by (0)

*

This work was supported, in whole or in part, by National Institutes of Health Grant R01 DK087764. The authors declare that they have no conflicts of interest with the contents of this article.

1

Both authors contributed equally to this work.

2

Recipient of Grant-in-aid scholarship 24-3549 from the Japan Society for the Promotion of Science.

3

Supported by Chinese Natural Science Foundation Fellowship 201306580015.